00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
21:19 , May 17, 2019 |  BioCentury  |  Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
19:11 , Dec 14, 2018 |  BC Week In Review  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...
18:27 , Dec 12, 2018 |  BC Extra  |  Financial News

NASH company Akero raises $70M, plans Phase IIa trial

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors...
14:54 , Sep 11, 2018 |  BC Extra  |  Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...
11:27 , Jun 25, 2018 |  BC Extra  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas...